Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Renalyx will continue operating as an independent unit within the group
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Subscribe To Our Newsletter & Stay Updated